Testing a combination treatment for a specific type of blood cancer

Plain-English translation of NCT03263572 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a combination of three drugs—, , and chemotherapy medications—to treat a specific type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). This is a genetic form of leukemia that tends to be harder to treat than other types of ALL. The study wants to see how well this medication combination works and how safe it is for patients with newly diagnosed disease or disease that has returned after previous treatment.

Philadelphia chromosome-positive ALL is a serious form of blood cancer that is difficult to cure with standard treatments. Researchers are testing whether combining this medication with traditional chemotherapy could help more patients achieve remission and live longer.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (either newly diagnosed, relapsed, or refractory)
you have adequate liver and pancreatic function based on blood tests
you are willing to use effective contraception during treatment and for 4 months after (if you can become pregnant or father a child)
you are generally well enough to tolerate treatment, based on your doctor's assessment

You likely don't qualify if…

you have an active serious infection that is not controlled by antibiotics
you have a history of pancreatitis (inflammation of the pancreas) in the past year or chronic pancreatitis
you have a history of alcohol abuse
you have very high triglyceride levels (over 650 mg/L) that cannot be controlled
you have another active cancer (other than certain skin cancers)

What participation looks like

You would receive the medication combination in cycles that repeat every 6 weeks. This involves receiving as a continuous intravenous infusion for 28 days, taking as a daily oral pill, and receiving chemotherapy medications injected into your spinal fluid on specific days. Treatment continues for up to 5 cycles (about 30 weeks) unless your disease gets worse or the side effects become too severe. After treatment ends, you would be followed up with visits at 30 days and then every 6 months to monitor your health.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Testing a combination treatment for a specific type of blood cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)